Purpose/Objective: SBRT aims to deliver high doses in few fractions, thus requiring high confidence in accuracy of the treatment planning and delivery process. Being one source of uncertainty, respiratory motion is usually accounted for by 4DCT imaging and deriving the internal target volume (ITV) as basis of the PTV definition. In doing so, variations of breathing patterns and motion-related underestimation of normal tissue dose are not considered. In this study, dose accumulation methods are proposed, incorporated into DVH computation, and applied for DVH analyses for SBRT plans of liver and lung lesions.
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Purpose/Objective: The 2D-bMLC concept aims to provide quick aperture modulation. We therefore developed a treatment planning system (TPS) for ultra-fast rotational IMRT with the 2D-bMLC. For dosimetric evaluation patient plans with delivery times of 20-60s per fraction were optimized and compared to standard step and shot IMRT plans. Materials and Methods: The 2D-bMLC consists of individually controlled absorbers arranged side by side forming a 2d aperture. The design, which leads to radiation fields fragmented into stripes (fig a) , aims at aperture changes below 100 ms. Within the TPS a treatment machine with a FFF 7MV linac source, a 2D-bMLC, a max dose rate of 2000 MU/min and a SAD of 800 mm was modeled. The total fraction dose is delivered in one gantry rotation with constant speed. Treatment plans are generated for a predefined delivery time T F (fig  b) . The TPS uses a PB dose algorithm and the 48 arc segments are approx. by fixed beam directions. For a prostate patient (patient I) median doses of 76 Gy and 70 Gy in 35 fraction were prescribed to the GTV and the PTV respectively. For the rectum a dose constraint of D 50% < 40 Gy was used. For Patient II with a nasopharyngeal carcinoma 54 Gy in 30 fractions were prescribed to the PTV and 66 Gy to the boost region. Constraints for the spinal cord were D 1% < 40 Gy, for the parotids D 50% < 30 Gy; D mean < 26 Gy. For both patients, plans with T F of 20s (plan P20), 30s (P30) and 60s (P60) were generated and compared to clinically accepted 9-field IMRT plans. D 99% , D 50% , D 1% , D mean , 95% coverage and inhomogeneity (TDI) for the targets as well as the mean dose to the normal tissue, excluding the PTV, were calculated. An additional tool was developed to compute the 2D-bMLC plans with a MC (Geant4.9.5) method, including a realistic model of the collimator absorber and gantry dynamic.
Results: All 2D-bMLC plans calculated with the TPS fulfill the clinical goals. In the table (fig c) , dose parameters are shown for patient I. Concerning the coverage and the TDI, the plans are in good agreement with the IMRT plan. Relative differences are below 1% while D 50% to the rectum was decreased with P60 and P30. For patient II, coverage of the boost region is reduced by ~1% while PTV coverage is improved from 91.0% (IMRT) to 97.2% (P60), 96.7% (P30), 94.7% (P20). TDI for the boost region is similar for all plans. D 1% to the spinal cord and D 50% and D mean to the parotids are slightly decreased (diff. < 3 Gy). D mean to the normal tissue is decreased by > 10%. Compared to the TPS calculations the MC computed plans show increased values of D 50% and D 1% for the targets as well as increased TDI. P30 and P20 might need rescaling to assure adequate target coverage. Also D mean to the normal tissue is increased in the MC plans. Conclusions: The 2D-bMLC plans fulfill the clinical goals and the relevant dosimetric parameters are comparable to the IMRT plans; Sparing of OARs is slightly improved. The 4D-MC tool allows to recompute the plans including the full dynamic of the delivery machine.
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Monte Carlo dosimetry for the Papillion P50 contact radiotherapy and IORT device A. Carver 1 , A. Gately 1 , R. Clements 1 , A. Nahum 1 1 Clatterbridge Cancer Centre, Department of Clinical Physics, Bebington Merseyside, United Kingdom Purpose/Objective: The Papillon P50 (Ariane Medical Systems, Derby, UK) is a relatively new radiotherapy treatment machine delivering low energy x-rays (50 kV generating potential) for contact radiotherapy and IORT (Intra-Operative Radiotherapy). In contact radiotherapy the end of the treatment machine is brought into contact with the tumour. The size of the field is small (<= 3 cm dia.) and the distance from the source to the tumour is very short (≈3-4 cm). In this study a Monte Carlo simulation of the Papillon P50 is created to verify that the parameters in the UK Dosimetry Code of Practice (Klevenhagen et al. 1996 , Phys. Med. Biol. 41, 2605 are applicable to this new regime: specifically backscatter factor, chamber factor and mass energyabsorption coefficient ratio. These values are currently extrapolated due to the short SSD and small field size. Materials and Methods: Geant 4 was used to construct a virtual representation of the Papillon P50 geometry. The beam spectrum of the Papillon P50 was simulated by creating a 50 keV electron beam which was incident upon the target. The resulting bremsstrahlung xray beam was then propagated through the simulated machine and into a phantom. A scoring plane at the surface of the phantom was used to compute the backscatter factor (B w ) and the mass-energy absorption coefficient ratio [(μ en /ρ) w/air ] air . The chamber factor (k ch ) was also measured experimentally by comparing the chamber reading with the dose obtained using the backscatter-factor method. Results: The HVL was calculated to be 0.9 mm Al similar to the experimental value of 0.77 mm Al. Simulated PDD curves agreed well with previous measurements. The mass-energy absorption coefficient for water to air at the surface of a water phantom was found to be 1.023 + 0.001 consistent with the value in the current UK code of practice for the same quality index. The backscatter factor was estimated to be 1.05 + 0.005 for an 11 mm field radius as shown by Figure 1 . This reduces the value of a dose measurement by approximately 1% relative to the current UK code of practice value based on published studies. The value of the chamber correction factor k ch obtained through measurement using low and very low energy codes was 1.04 + 0.01, lower than the 1.06 currently in the code of practice but within the uncertainties in the original studies.
Conclusions:
The values for the calibration coefficients generated in this study are close to those in the UK code of practice. A difference of 2% was found for the chamber factor but this coefficient is known to be subject to large uncertainties of which the code of practice gives a representative value. Work is continuing to model the PTW23342 ionisation chamber and produce a chamber factor via Monte Carlo simulation. Initial results are higher than experimental values. where N is the number of simulated histories. By employing a K-fold recycling of the PSF particles equation 1 can be rewritten as
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The total variance can be represented as a function of K -1 and fitted to a straight line. The latent variance of the PSF is given by the crossing of this line with the axis K -1 =0. The most recent TrueBeam PSFs were downloaded from myVarian.com. A 10×10 cm 2 field was simulated in BEAMnrc using combined and trigometrically 'flattened' PSFs for each energy and fluence mode as input. No variance reductions were employed and PSFs were scored at 90 cm SSD. DOSXYZnrc was employed to score dose in a 40×40×40 cm 3 homogeneous water phantom using the 10×10 cm 2 field PSFs as input directly on the phantom surface. The voxel size was 0.25×0.25×0.25 cm 3 and the variance in the 27 voxels located around the beam isocenter was scored. Results: The total variance, q, as a function of the inverse recycling rate, K -1 , is shown in figure 1 . The latent SD for each energy and mode is shown in table 1. In proton therapy, complex density heterogeneities within the beam path pose a challenge to analytical dose calculation algorithms so that the reliability of the predicted dose distributions might be questioned. For these cases in which substantial dose errors are expected, resorting to more accurate Monte Carlo (MC) simulations might be essential to ensure a successful treatment outcome and therefore the benefit is worth a presumably long computation time. The aim of this study was to obtain a geometrical indicator for the accuracy of dose delivery based on analytical dose calculations for proton therapy fields.
